69 related articles for article (PubMed ID: 10994142)
1. Follow-up of prostate carcinoma patients treated with total androgen blockade by repeated map-biopsy.
Szabo J; Bartok K; Keréni T; Vegh A; Romics I; Szende B
Ann Urol (Paris); 2000 Aug; 34(4):236-9. PubMed ID: 10994142
[TBL] [Abstract][Full Text] [Related]
2. [The role of repeated biopsies in prognosis of prostate cancer].
Romics I; Lovász S; Szabó J; Szomor L; Minik K; Bartók K; Kerényi T; Szende B
Orv Hetil; 2002 Jul; 143(27):1619-23. PubMed ID: 12179998
[TBL] [Abstract][Full Text] [Related]
3. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
5. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation.
Szende B; Romics I; Torda I; Bély M; Szegedi Z; Lovász S
Urol Int; 1999; 63(2):115-9. PubMed ID: 10592500
[TBL] [Abstract][Full Text] [Related]
7. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
Pether M; Goldenberg SL; Bhagirath K; Gleave M
Can J Urol; 2003 Apr; 10(2):1809-14. PubMed ID: 12773232
[TBL] [Abstract][Full Text] [Related]
8. Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression.
Augustin H; Freibauer C; Bayer L; Lunglmayr G; Tschurlovich F; Kuber W; Pummer K
Prostate Cancer Prostatic Dis; 2006; 9(3):279-83. PubMed ID: 16702984
[TBL] [Abstract][Full Text] [Related]
9. GnRH receptor and androgen receptor status and outcome of advanced prostate carcinomas.
Szabó J; Bartók K; Krenács T; Szepesváry Z; Szende B
Anticancer Res; 2009 Feb; 29(2):681-4. PubMed ID: 19331222
[TBL] [Abstract][Full Text] [Related]
10. Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma.
Szende B; Romics I; Minik K; Szabó J; Torda I; Lovász S; Szomor L; Tóth L; Bély M; Kerényi T; Bartók K; Végh A
Prostate; 2001 Oct; 49(2):93-100. PubMed ID: 11582587
[TBL] [Abstract][Full Text] [Related]
11. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
[TBL] [Abstract][Full Text] [Related]
13. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy.
Cowen D; Troncoso P; Khoo VS; Zagars GK; von Eschenbach AC; Meistrich ML; Pollack A
Clin Cancer Res; 2002 May; 8(5):1148-54. PubMed ID: 12006531
[TBL] [Abstract][Full Text] [Related]
14. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
17. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results.
Wachter-Gerstner N; Wachter S; Goldner G; Nechvile E; Pötter R
Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.
Ueno S; Namiki M; Fukagai T; Ehara H; Usami M; Akaza H
Int J Urol; 2006 Dec; 13(12):1494-500. PubMed ID: 17118024
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
Shulman MJ; Karam JA; Benaim EA
Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
